文献速递自身炎症与 IgG4 相关病

BNT162b2 mRNA COVID-19疫苗在家族性地中海热患者中的安全性

Safety of the BNT162b2 mRNA COVID-19 vaccine in patients with familial Mediterranean fever.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

本研究纳入273例符合家族性地中海热(FMF)诊断标准、年龄大于18岁且至少接种一剂BNT162b2疫苗的患者,通过电子病历和电话访谈收集接种后副作用及疾病发作情况。结果显示局部反应率第一剂65.5%、第二剂60%,全身不良事件率第一剂26%、第二剂50.4%,均低于一般人群报告率;接种后FMF活动度在多数患者中保持稳定,无患者报告心包炎或心肌炎发作。结论认为BNT162b2 mRNA COVID-19疫苗在FMF患者中安全,结果支持根据适用于一般人群的指南为该类患者接种此疫苗。

要点

  • 273例FMF患者中超过95%接种了两剂BNT162b2疫苗,局部反应率第一剂65.5%、第二剂60%。
  • 全身不良事件率第一剂26%、第二剂50.4%,低于一般人群真实世界和临床试验报告率。
  • 接种后FMF活动度在多数患者中保持稳定,无患者报告心包炎或心肌炎发作。

核心结论

  • BNT162b2 mRNA COVID-19疫苗在FMF患者中安全,结果支持根据适用于一般人群的指南为该类患者接种此疫苗。

研究设计与样本

  • 本研究纳入273例符合FMF诊断标准、年龄大于18岁且至少接种一剂BNT162b2疫苗的患者,通过电子病历和电话访谈收集基线特征、FMF特征、接种后副作用及疾病发作数据。

主要发现

  • 超过95%的FMF患者接种了两剂疫苗。
  • 局部反应率第一剂为65.5%、第二剂为60%,全身不良事件率第一剂为26%、第二剂为50.4%,均低于一般人群真实世界和临床试验报告率。
  • 接种后FMF活动度在多数患者中保持稳定。
  • 无患者报告心包炎或心肌炎发作。
  • FMF疾病活动度更高的患者和携带M694V突变的患者接种后全身副作用和发作率显著更高。

临床怎么用

  • 作者结论认为BNT162b2 mRNA COVID-19疫苗在FMF患者中安全,结果支持根据适用于一般人群的指南为该类患者接种此疫苗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Evidence suggests a possible association between the COVID-19 vaccine and autoimmune disease flares or new onset of various autoinflammatory manifestations, such as pericarditis and myocarditis. The objective of this study was to assess the safety of an mRNA-based BNT162b2 anti-COVID-19 vaccine in individuals with FMF, a prototypic autoinflammatory disease. METHODS: Patients participating in this study fulfilled the criteria for diagnosis of FMF, were older than 18 years and received at least one dose of the vaccine. Data on baseline characteristics, features of FMF, post-vaccination side effects, and disease flares were acquired using electronic medical files and telephone interviews. RESULTS: A total of 273 FMF patients were recruited for the study. >95% were vaccinated with two doses of the vaccine. The rates of local reactions following the first and second vaccine doses were 65.5% and 60%, respectively, and 26% and 50.4%, respectively, for systemic adverse events. These rates are lower than those reported for the general population from real-world and clinical trial settings. Postvaccination FMF activity remained stable in most patients. None of the patients reported an attack of pericarditis or myocarditis, considered the most serious vaccine-associated adverse events. Patients with a more active FMF disease and patients harboring the M694V mutation had a significantly higher rate of post-vaccination systemic side effects and attacks. CONCLUSION: The BNT162b2 mRNA COVID-19 vaccine is safe in patients with FMF. Our results support the administration of this vaccine to FMF patients according to guidelines applicable to the general population.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Shechtman L, Lahad K, Livneh A, et al. Safety of the BNT162b2 mRNA COVID-19 vaccine in patients with familial Mediterranean fever. Rheumatology (Oxford). 2022. PMID: 35238382. doi:10.1093/rheumatology/keac131

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。